TNF-Related Apoptosis-Inducing Ligand
"TNF-Related Apoptosis-Inducing Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane-protein belonging to the TNF family of intercellular signaling proteins. It is a widely expressed ligand that activates APOPTOSIS by binding to TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTORS. The membrane-bound form of the protein can be cleaved by specific CYSTEINE ENDOPEPTIDASES to form a soluble ligand form.
| Descriptor ID |
D053221
|
| MeSH Number(s) |
D12.644.276.374.750.625 D12.776.467.374.750.625 D23.529.374.750.625
|
| Concept/Terms |
TNF-Related Apoptosis-Inducing Ligand- TNF-Related Apoptosis-Inducing Ligand
- Apoptosis-Inducing Ligand, TNF-Related
- TNF Related Apoptosis Inducing Ligand
- Apo-2 Ligand
- Apo 2 Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 10
- Apo-2L Protein
- Apo 2L Protein
- TNF Superfamily, Member 10
- CD253 Antigen
- Antigen, CD253
- TRAIL Protein
|
Below are MeSH descriptors whose meaning is more general than "TNF-Related Apoptosis-Inducing Ligand".
Below are MeSH descriptors whose meaning is more specific than "TNF-Related Apoptosis-Inducing Ligand".
This graph shows the total number of publications written about "TNF-Related Apoptosis-Inducing Ligand" by people in this website by year, and whether "TNF-Related Apoptosis-Inducing Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 3 | 3 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "TNF-Related Apoptosis-Inducing Ligand" by people in Profiles.
-
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 Jul; 643(8070):219-229.
-
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Mol Cancer Ther. 2017 07; 16(7):1290-1298.
-
The C5a anaphylatoxin receptor (C5aR1) protects against Listeria monocytogenes infection by inhibiting type 1 IFN expression. J Immunol. 2014 Nov 15; 193(10):5099-107.
-
Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69.
-
Rapamycin inhibits Toll-like receptor 4-induced pro-oncogenic function in head and neck squamous cell carcinoma. Oncol Rep. 2014 Jun; 31(6):2804-10.
-
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
-
Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther. 2014 Jan; 22(1):140-8.
-
Tunable thioesters as "reduction" responsive functionality for traceless reversible protein PEGylation. J Am Chem Soc. 2013 Jul 31; 135(30):10938-41.
-
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 2013 Aug; 14(8):711-9.
-
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.